{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "XTLB",
  "name": "XTL Biopharmaceuticals Ltd.",
  "url": "https://frontierpicks.com/dossiers/XTLB/",
  "json_url": "https://frontierpicks.com/dossiers/XTLB.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Delisting binary fully resolved — Nasdaq confirmed compliance 2026-07-20 — and the pivot pop has bled off: no dated company release since, ADS $2.94 (2026-07-25) → $2.79 (2026-08-14), RSI 44.4. Event narrative is saturated; the next leg needs a first-trial-commencement or financing 6-K against a ~$7M cap carrying a going-concern flag and milestone dilution.",
  "invalidation_trigger": "A weekly close below $2.70 loses the private-placement clearing price — the last level at which capital actually cleared — and opens the pre-merger range; a Nasdaq equity-rule breach notice under the one-year monitor, or a milestone/authorized-share issuance into the micro float, confirms the de-rating.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "m-and-a-special-situations",
    "small-cap-value-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Foreign private issuer: reports via irregular 6-K, no scheduled quarterly US earnings date — material news can drop in any session.",
    "Dual-listed on Nasdaq; the Israeli session trades ahead of the US open and can gap the ADS.",
    "Nasdaq Mandatory Panel Monitor runs to ~2027-07-20; an equity-rule breach inside the window triggers delisting with no cure period, only a new hearing request.",
    "Share-count feeds are unreliable after the 1-for-4 reverse split effective 2026-03-25 and the 2026-06-30 issuance — anchor on market cap, not per-share float figures.",
    "The FY2025 Form 20-F carries a going-concern warning that survived the Psyga acquisition.",
    "Legacy hCDR1/Edratide (SLE/Sjogren's, Yeda license) and rHuEPO assets are dormant and are not the current story."
  ],
  "body_markdown": "## Current Thesis\nThe delisting binary that gave this name its structure is fully resolved and fully spent. Nasdaq confirmed regained compliance on 2026-07-20 across the public-interest, periodic-filing, bid-price and stockholders'-equity rules, with a one-year Mandatory Panel Monitor attached. Since that confirmation, nothing dated has followed: the company's newswire shows no release after the 2026-06-30 Psyga Bio completion, and the ADS has drifted from $2.94 on 2026-07-25 to a $2.79 close on 2026-08-14 with RSI(14) at 44.4. What an investor is buying at this level is no longer an event with a defined payoff — it is a ~$7M psilocybin micro-cap with a going-concern warning, a milestone-dilution overhang and no scheduled catalyst, sitting roughly 3% above the $2.70 price at which the last capital actually cleared. The narrative leg that would restart this is operational, not structural: a first Phase 2a commencement 6-K, or a financing that puts a disclosed runway on the balance sheet.\n\n## Bull Case\n- **Compliance closed, not deferred (2026-07-20).** Every open deficiency — public-interest, delinquent filing, bid price, stockholders' equity — was confirmed cured. The independent delisting risk live at the 2026-05-22 Staff Delist Determination is off the table for now.\n- **The merger closed on the cliff date (2026-06-30).** XTL holds ~83.40% of Psyga Bio's fully diluted capital and continues to trade on Nasdaq and TASE.\n\n- **The last priced capital came from an insider.** The $1.5M private placement funded at close at $2.70/ADS was led by director Alexander Rabinovitch — a purchase, not a sale, and 3% below the 2026-08-14 close.\n- **The float absorbed the merger consideration without losing the shelf.** ~33.36% of capital was issued to Psyga holders at the 2026-06-30 close, and the 3-month return through 2026-08-14 is still +6.7%.\n\n## Bear Case\n- **The monitor has no cure period.** The Mandatory Panel Monitor running to roughly 2027-07-20 means any equity-rule breach inside the window produces an automatic Delist Determination — only a new hearing request, no compliance plan.\n- **Going-concern survived the deal.** The FY2025 Form 20-F carries the flag after the pivot. $1.5M does not fund seven Phase 2a trials plus new studies.\n- **Dilution is the structural story, and it is authorized.** Beyond the ~33.36% issued at close, up to a further ~25% is tied to three clinical/commercial milestones, and the 2026-06-29 EGM lifted authorized capital to 5.8B shares.\n- **The tape since the event is give-back.** From $2.94 on 2026-07-25 to $2.79 on 2026-08-14, with no company release in between. Effectively the whole 3-month return sits in the single 2026-06-30 gap.\n- **Structure is a downtrend, not a base.** -91.5% from the $32.80 52-week high on split-adjusted bars; the 1-for-4 reverse split effective 2026-03-25 is already inside that adjusted series.\n\n## Setup & Price Structure\n- **Reference close 2026-08-14: $2.79.** RSI(14) 44.4 — no momentum condition in either direction, which is what post-event drift looks like on a name whose news flow stopped.\n- **$2.70 is the tightest defined level on the chart** — the clearing price of the placement that funded at the 2026-06-30 close. It sits about 3% under the last close and is the only recent price at which size changed hands.\n- **The narrative is saturated.** Dated by three points — 2026-06-30 (merger close, the ~+90% intraday spike that cleared the 200-DMA for the first time in three months, peak attention), 2026-07-20 (compliance confirmation, the last dated milestone), and the roughly three-and-a-half weeks to 2026-08-14 with no new headline and a lower close. The compliance headline did not bring a new bid; it marked where the old one stopped.\n- **Crowding and positioning observables.** There is no scheduled US earnings date — as a foreign private issuer XTL reports via irregular 6-K, so nothing in the calendar compresses the range. Issuance into the event is documented and large relative to the float (~33.36% at close, up to ~25% in earn-outs, 5.8B shares authorized 2026-06-29) against a market cap the 2026-07-25 coverage put near $7.1M at $2.94. The only recent insider transaction on record runs the other way — the director-led $1.5M placement at $2.70. Retail-sentiment coverage is not clustering; the newswire has been silent since 2026-06-30.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-16 → 2026-09-15 (unscheduled):** 6-K announcing commencement or first patient enrollment in a Psyga Phase 2a psilocybin trial. First operational evidence behind the pivot; also the first tick on the milestone clock.\n- **2026-08-16 → 2026-09-15 (unscheduled):** follow-on financing 6-K. The pricing of the next raise resets the reference the ADS trades against; $2.70 is the incumbent.\n- **No scheduled US earnings date in the window.** Foreign private issuer — no quarterly print, no confirmed date to trade into or around.\n- **Outside the window, hard-dated:** ~2027-06-30, deadline for commencement of at least three human clinical trials within 12 months of the 2026-06-30 close; ~2027-07-20, expiry of the Nasdaq Mandatory Panel Monitor.\n\n## What Would Change Our Mind\n- **The $2.70 shelf giving way is the structural break.** That price is where the last capital cleared, and losing it says the market is pricing going-concern and milestone dilution above the psilocybin pivot: a weekly close below $2.70 ends the \"resolved to the survive side\" frame and opens the pre-merger range.\n- **A Nasdaq equity-rule breach notice inside the monitor window** would re-open the delisting tail on worse terms than the one that just closed — automatic determination, no cure period.\n- **A financing priced under the placement level**, or a milestone issuance dropped into the micro float, confirms the supply side of the bear case in a checkable way.\n- **The upside change-of-mind is symmetric and equally dated:** a 6-K confirming first Phase 2a dosing alongside a raise that discloses a runway, with the ADS holding the 2026-06-30 gap, converts a story with no catalyst into one with a schedule.\n- **Continued silence is itself information.** Another 30–60 days without a commencement release compresses the runway to the ~2027-06-30 three-trial milestone.\n\n## Correlation Notes\n- Headline exposure to the psychedelics complex (COMPASS Pathways, atai, Cybin) and to FDA news in the psilocybin class is real, but no measured correlation is asserted here — at roughly $7M market cap, single-name 6-K risk swamps theme beta.\n- Dual-listed on Nasdaq and TASE. The Israeli session trades ahead of the US open and can gap the ADS on news furnished in Tel Aviv first.\n- Micro-cap biotech risk appetite (XBI, small-cap breadth) is a secondary driver; liquidity is the first-order one — a name this size prints 20%+ moves on order flow rather than information.\n- The legacy hCDR1/Edratide programme (SLE/Sjögren's, Yeda license) and rHuEPO are dormant and carry no read-through to the current tape.",
  "first_seen": "2026-04-30",
  "last_analyzed": "2026-08-16T13:01:55+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}